TW202330618A - 抗ｃｄｈ６抗體及其抗體－藥物偶聯物 - Google Patents

抗ｃｄｈ６抗體及其抗體－藥物偶聯物 Download PDF

Info

Publication number
TW202330618A
TW202330618A TW111147444A TW111147444A TW202330618A TW 202330618 A TW202330618 A TW 202330618A TW 111147444 A TW111147444 A TW 111147444A TW 111147444 A TW111147444 A TW 111147444A TW 202330618 A TW202330618 A TW 202330618A
Authority
TW
Taiwan
Prior art keywords
seq
amino acid
acid sequence
sequence shown
antigen
Prior art date
Application number
TW111147444A
Other languages
English (en)
Chinese (zh)
Inventor
遜 孟
淑惠 劉
史靜
Original Assignee
大陸商普衆發現醫藥科技（上海）有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2021/136994 external-priority patent/WO2023102875A1/en
Application filed by 大陸商普衆發現醫藥科技（上海）有限公司 filed Critical 大陸商普衆發現醫藥科技（上海）有限公司
Publication of TW202330618A publication Critical patent/TW202330618A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW111147444A 2021-12-10 2022-12-09 抗ｃｄｈ６抗體及其抗體－藥物偶聯物 TW202330618A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/CN2021/136994 WO2023102875A1 (en) 2021-12-10 2021-12-10 Anti-cdh6 antibody drug conjugate
CN202111507685 2021-12-10
CN202111507685.5 2021-12-10
WOPCT/CN2021/136994 2021-12-10

Publications (1)

Publication Number Publication Date
TW202330618A true TW202330618A (zh) 2023-08-01

Family

ID=86729685

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111147444A TW202330618A (zh) 2021-12-10 2022-12-09 抗ｃｄｈ６抗體及其抗體－藥物偶聯物

Country Status (11)

Country Link
US (1) US20250090677A1 (enExample)
EP (1) EP4444360A4 (enExample)
JP (1) JP2024545170A (enExample)
KR (1) KR20240130160A (enExample)
CN (1) CN118302199A (enExample)
AU (1) AU2022406708A1 (enExample)
CA (1) CA3239715A1 (enExample)
IL (1) IL313227A (enExample)
MX (1) MX2024007035A (enExample)
TW (1) TW202330618A (enExample)
WO (1) WO2023104188A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240238440A1 (en) * 2021-04-29 2024-07-18 Hyslink Therapeutics Preparation method for and application of antibody conjugated drug
AU2024236246A1 (en) 2023-03-14 2025-10-30 Daiichi Sankyo Company, Limited Combination of anti-CDH6 antibody-drug conjugate and VEGF inhibitor
JPWO2024204679A1 (enExample) 2023-03-31 2024-10-03
WO2026082031A1 (zh) * 2024-10-14 2026-04-23 先声再明医药股份有限公司 一种包含抗cdh6抗体或其adc的药物组合物
WO2026120507A1 (en) 2024-12-04 2026-06-11 Daiichi Sankyo Company, Limited An antibody-drug conjugate for use in the treatment of drug-resistant cancer
WO2026130458A1 (zh) * 2024-12-19 2026-06-25 上海齐鲁制药研究中心有限公司 一种抗cdh6抗体、其偶联物及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017001946A (es) * 2014-08-12 2017-06-19 Novartis Ag Conjugados de farmacos con anticuerpos anti-cdh6.
US10829560B2 (en) * 2015-04-20 2020-11-10 Consejo Superior De Investigaciones Cientificas Agents binding specifically to human cadherin-17, human cadherin-5, human cadherin-6 and human cadherin-20 RGD motif
WO2018185618A1 (en) * 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
TWI926682B (zh) * 2017-05-15 2026-05-21 日商第一三共股份有限公司 抗體－藥物結合物之製造方法
CA3119956A1 (en) * 2018-11-14 2020-05-22 Daiichi Sankyo Company, Limited Anti-cdh6 antibody-pyrrolobenzodiazepine derivative conjugate

Also Published As

Publication number Publication date
AU2022406708A1 (en) 2024-06-27
MX2024007035A (es) 2024-06-21
CA3239715A1 (en) 2023-06-15
EP4444360A4 (en) 2026-06-17
JP2024545170A (ja) 2024-12-05
WO2023104188A1 (en) 2023-06-15
IL313227A (en) 2024-07-01
KR20240130160A (ko) 2024-08-28
CN118302199A (zh) 2024-07-05
EP4444360A1 (en) 2024-10-16
US20250090677A1 (en) 2025-03-20

Similar Documents

Publication Publication Date Title
JP7401126B2 (ja) 抗ｃｕｂドメイン含有タンパク質１（ｃｄｃｐ１）抗体、抗体薬物コンジュゲート、およびその使用方法
AU2016286898B2 (en) Method for selectively manufacturing antibody-drug conjugate
JP7842217B2 (ja) 抗Ｎｅｃｔｉｎ－４抗体、抗体薬物複合体、その製造方法及び使用
WO2023102875A1 (en) Anti-cdh6 antibody drug conjugate
KR101916553B1 (ko) 항-her2 항체-약물 접합체
WO2023104188A1 (en) Anti-cdh6 antibodies and antibody-drug conjugates thereof
CN118159300A (zh) 一种抗体及其药物偶联物和用途
CN110575547B (zh) 靶向于tf的抗体-药物偶联物及其制法和用途
BR112019023832A2 (pt) anticorpo, fragmento funcional do anticorpo, polinucleotídeo, vetor de expressão, células hospedeiras, métodos para produzir um anticorpo de interesse ou um fragmento funcional do anticorpo, para tratamento de um tumor e para produzir um conjugado anticorpo-fármaco, conjugado anticorpo-fármaco, e, composição farmacêutica
JP2018516539A (ja) 抗ｃ−Ｍｅｔ抗体および抗ｃ−Ｍｅｔ抗体−細胞毒性薬物複合体ならびにそれらの医薬用途
CN110577600B (zh) 靶向gpc3的抗体-药物偶联物及其制备方法和用途
CN117693526A (zh) 抗-c-Met抗体药物缀合物
KR20230041023A (ko) 항체-약물 콘주게이트의 제조 방법
CN110575548A (zh) 靶向于cd73的抗体-药物偶联物及其制法和用途
WO2024240227A1 (en) Antibodies and antibody-drug conjugates thereof
JP2025523605A (ja) 抗ｆｇｆｒ３抗体コンジュゲート及びその医療用途
KR20250090287A (ko) 항체, 항체-약물 접합체, 이의 제조 및 용도
CN121986119A (zh) 人源化muc1抗体和抗体药物缀合物
CN120424212A (zh) 抗FGFR2b抗体及抗体药物偶联物
JP2025535442A (ja) 抗体－薬物コンジュゲート、その調製方法、および、その抗腫瘍への使用
HK40107995A (en) Anti-cdh6 antibodies and antibody-drug conjugates thereof
WO2025026338A1 (zh) 具有高药物负载的抗体-药物缀合物及其用途
CA3300455A1 (en) Antibody-drug conjugate having high drug load and use thereof
TW202608927A (zh) 多特異性抗體－藥物偶聯物
AU2024269443A1 (en) Anti-epidermal growth factor receptor (egfr) antibody-drug conjugate and use thereof